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Pancreatic cancer is an aggressive and potent disease, which is largely resistant to conventional forms of treatment. However,
the discovery of antigens associated with pancreatic cancer cells has recently suggested the possibility that immunotherapy
might become a speciﬁc and effective therapeutic option. T cells within many epithelia, including those of the pancreas, are
known to express the aEb7-integrin adhesion molecule, CD103. The only characterised ligand for CD103 is E-cadherin, an
epithelial adhesion molecule which exhibits reduced expression in pancreatic cancer. In our study, CD103 was found to be
expressed only by activated T cells following exposure to tumour necrosis factor beta 1, a factor produced by many cancer
cells. Signiﬁcantly, the expression of this integrin was restricted mainly to class I major histocompatibility complex-restricted
CD8+ T cells. The human pancreatic cancer cell line Panc-1 was transfected with human E-cadherin in order to generate E-
cadherin negative (wild type) and positive (transfected) sub-lines. Using a sensitive ﬂow cytometric adhesion assay it was found
that the expression of both CD103 (on T cells) and E-cadherin (on cancer cells) was essential for efﬁcient adhesion of
activated T cells to pancreatic cancer cells. This adhesion process was inhibited by the addition of antibodies speciﬁc for
CD103, thereby demonstrating the importance of the CD103?E-cadherin interaction for T-cell adhesion. Using a
51Cr-
release cytotoxicity assay it was found that CD103 expressing T cells lysed E-cadherin expressing Panc-1 target cells following
T cell receptor stimulation; addition of antibodies speciﬁc for CD103 signiﬁcantly reduced this lysis. Furthermore, absence of
either CD103 from the T cells or E-cadherin expression from the cancer cells resulted in a signiﬁcant reduction in cancer cell
lysis. Therefore, potentially antigenic pancreatic cancer cells could evade a local anti-cancer immune response in vivo as a
consequence of their loss of E-cadherin expression; this phenotypic change may also favour metastasis by reducing homotypic
adhesion between adjacent cancer cells. We conclude that effective immunotherapy is likely to require upregulation of E-
cadherin expression by pancreatic cancer cells or the development of cytotoxic immune cells that are less dependent on this
adhesion molecule for efﬁcient effecter function.
British Journal of Cancer (2002) 87, 1034–1041. doi:10.1038/sj.bjc.6600597 www.bjcancer.com
ã 2002 Cancer Research UK
Keywords: pancreatic cancer; immunotherapy; cytotoxic; T cells; E-cadherin
A number of tumour-associated antigens have been described in
pancreatic carcinoma (McKenzie and Apostolopoulos, 1999). These
include MUC-1 (Ho and Kim, 1994), Pancreatic Associated Protein
(PAP) (Motoo et al, 1998), Her2/neu (Yamanaka et al, 1993), and
K-ras (Berndt et al, 1998). Furthermore, a recent in vitro study by
Schnurr et al (2001) suggests that these antigens may be important
for T cell recognition and lysis of autologous pancreatic cancer
cells. Despite the ability of autologous T cells to speciﬁcally recog-
nize tumour-associated antigens it is clear that antigenic tumours
in vivo successfully evade the immune system, demonstrated by
their proliferative and metastatic nature. Several hypotheses have
been proposed to explain the failure of the immune system to clear
the cancer cells. These include secretion of immunosuppressive
cytokines (Chouaib et al, 1997), induction of apoptosis in the inﬁl-
trating T-cell population (Igney et al, 2000), down-regulation of
target cell membrane molecules such as MHC class I and II
(Scupoli et al, 1996), and down regulation of adhesion molecules
(Pettit et al, 2000).
Adhesion between lymphocytes and their targets is thought to be
a prerequisite for effective recognition and cytotoxicity. Hence,
adhesive interactions between pancreatic cancer cells and cytotoxic
T cells may be crucial to an effective anti-cancer immune response.
The interaction between lymphocyte function associated antigen-1
(LFA-1) expressed by lymphocytes and intercellular adhesion mole-
cule (ICAM-1) on antigen presenting cells is known to be
important for adhesion (Takahashi et al, 1993). LFA-1 is a member
of the b2 integrin family of molecules and has been shown to
transduce ‘outside–in’ signalling that can augment T lymphocyte
activation (Dubey et al, 1995). It has also been demonstrated that
the LFA-1?ICAM-1 interaction can increase T-cell cytotoxicity by
causing mobilisation of cytotoxic granules, whilst antibody block-
ade of this interaction causes a reduction in cytotoxicity (Zhou
et al, 1998). However, it is not clear whether additional adhesion
receptor systems can play an important role in this process.
The aEb7 heterodimer, often referred to as CD103 (an epitope
of the a subunit), is a recently discovered member of the integrin
family. It is expressed by over 90% of lymphocytes in the intestinal
epithelium and 40% of lymphocytes in gut lamina propria (Cerf-
Bensussan et al, 1987). Similar expression by lymphocytes has been
reported in the lung (Rihs et al, 1996), salivary gland (Fujihara et
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(Ebert et al, 1998). As the aEb7 integrin is found on fewer than 2%
of circulating lymphocytes (Cerf-Bensussan et al, 1987), it is
considered a marker for intraepithelial lymphocytes (IEL).
The only characterised ligand for aEb7 is the cell adhesion mole-
cule E-cadherin. When E-cadherin negative cells were transfected
with E-cadherin it was found that a greater proportion of IEL
was able to bind; this increase was inhibited by speciﬁc adhesion
molecule blocking antibodies (Cepek et al, 1994). It has also been
demonstrated that the aEb7 integrin, in common with LFA-1, may
have co-stimulatory properties (Sillett et al, 1999). For example,
IEL-mediated cytolysis is enhanced via an unknown intracellular
signalling pathway if the aEb7 integrin is cross-linked with anti-
body (Roberts and Kilshaw, 1993). Furthermore, IEL have a
greater capacity than peripheral blood lymphocytes (PBL) for
spontaneous cytotoxicity of epithelial cells (Taunk et al, 1992).
E-cadherin is a trans-membrane protein expressed primarily by
epithelial cells, where it stabilises the homotypic adhesion crucial
for development and maintenance of functioning epithelium
(Gumbiner, 1996). Approximately 90% of human malignancies
are of epithelial origin. E-cadherin is known to have tumour
suppressor effects (Frixen et al, 1991; Christofori and Semb,
1999), and reduced expression during cancer development has been
observed in many epithelial cancers including breast adenocarcino-
ma (Berx et al, 1995), ovarian carcinoma (Davies et al, 1998) and
pancreatic adenocarcinoma (El-Hariry et al, 1999). In pancreatic
cancer, loss of E-cadherin expression is associated with high grade
and advanced stage (Pignatelli et al, 1994; Karayiannakis et al,
1998), and is a marker of poor prognosis (Kuniyasu et al, 1999).
As over 90% of mucosal T cells express an adhesive counter-
receptor speciﬁc only for E-cadherin, it is likely that this interac-
tion performs a physiologically important role within the
epithelial compartment. This has not been deﬁned but potentially
provides a mechanism to enhance antigen recognition within the
epithelium. Indeed, it has been proposed that IEL may be respon-
sible for speciﬁc immunosurveillance within anatomically
vulnerable epithelia (Kilshaw and Karecla, 1996), having a potential
to eliminate both infected and cancerous epithelial cells. Clearly,
interaction between the aEb7 integrin and E-cadherin does not
function in isolation and other molecules are likely to be involved
in IEL function, including the LFA-1?ICAM-1 system. Although
ICAM-1 is absent from gut (Bloom et al, 1995) and normal
pancreatic epithelium (Shimoyama et al, 1997) it has been demon-
strated at varying levels on pancreatic carcinoma cells (Shimoyama
et al, 1997), and its expression can be increased by TNFa and IFNg
stimulation (Shimoyama et al, 1999).
The current study was designed to examine the role of the
aEb7?E-cadherin interaction in pancreatic cancer. An E-cadherin
negative pancreatic carcinoma cell line was transfected with human
E-cadherin cDNA. Cells expressing E-cadherin were selected for
investigation of the potential of this molecule to increase the adhe-
sion of T cells that had been induced to express the aEb7-integrin.
Following deﬁnition of the conditions required for T cell adhesion,
a series of experiments was performed to determine whether inter-
action with E-cadherin can increase the lysis of pancreatic cancer
cells by CD103+ T cells.
MATERIALS AND METHODS
Antibodies
Studies were performed using murine anti-human E-cadherin
(Clone 67A4; Immunotech), murine anti-human ICAM-1
(Clone84H10; Serotec), murine anti-human CD45:RPE (Clone
T29/33; DAKO), murine anti-human CD103 (Clone Ber-ACT8;
DAKO), murine anti-human CD3 (OKT3; Janssen–Cilag, Buckin-
ghamshire, UK), murine anti-human CD11a (a subunit of LFA-1,
Clone MHM24; DAKO), murine anti-human CD18 (b subunit of
LFA-1, Clone MHM23; DAKO), murine IgG1 (isotype control
X0931, DAKO).
Cell culture
A pancreatic carcinoma cell line, Panc-1, was used in these experi-
ments. Panc-1 was developed from an undifferentiated pancreatic
carcinoma of ductal origin (Lieber et al, 1975) (ECACC No
87092802; ECACC, Porton Down, UK). Cell lines were cultured
in DMEM complete medium (Life Technologies, Paisley, UK)
containing 10% foetal calf serum (Sigma, UK), penicillin and strep-
tomycin (Life Technologies). Cell lines were routinely passaged
when conﬂuent. Transfected Panc-1 cells were cultured as above
with the addition of hygromycin B (350 mgm l
71). Medium
(including hygromycin B) was replaced every 2 days. Epstein Barr
virus transformed B-lymphocytes (EBV-BCL) were obtained from
ECACC. These were cultured in RPMI 1640 complete medium
(Life Technologies) containing 10% foetal calf serum (Sigma,
UK), penicillin and streptomycin (Life Technologies).
Preparation of CD103+ lymphocytes
Fresh peripheral blood lymphocytes (PBL) were obtained from
normal healthy volunteers. Whole blood was diluted with an equal
volume of RPMI 1640. The resultant suspension was divided into
10 ml aliquots and separated by density centrifugation over
Ficoll-Paque (Nycomed, UK) at 400 g for 25 min. The interfacial
layer consisting of mononuclear cells was recovered and washed
in RPMI 1640. The pellet of cells was re-suspended in complete
medium and incubated in a horizontal 25 cm
72 tissue culture ﬂask
(Corning, UK) for 1 h to allow the monocyte population to adhere
to the plastic. The non-adherent lymphocyte population was gently
re-suspended, removed and the cells counted. From this popula-
tion, T-lymphocytes were selected using an immunomagnetic T
cell negative isolation kit (Dynal, Wirral, UK) in order to remove
natural killer cell activity. Brieﬂy, cells were incubated with an anti-
body mixture containing antibodies speciﬁc for CD14
(Macrophages), CD16 (Granulocytes and NK cells), CD56 (NK
cells), HLA class II DR/DP (B cells). Subsequent incubation with
Dynabeads captured the antibody-bound cells. The coated cells
were then separated with a magnet and discarded, leaving a pure
T lymphocyte population.
Irradiated EBV-BCL (50 Gy;
137Cs source) were added to the T
lymphocyte suspension at a ratio of 2:1 (stimulators:responders).
This one-way MLR was divided into two 25 cm
72 tissue culture
ﬂasks, which were incubated at 458 to the horizontal at 378C for
5 days. This step allows activation and proliferation of allo-speciﬁc
PBL to provide large numbers of activated human T lymphocytes.
After 5 days recombinant TGFb1 (R&D Systems, UK) was added to
one ﬂask at a concentration of 3 ng ml
71. Incubation of both
ﬂasks continued at 378C until day 8 or 9 when the cells were
retrieved. The viable population was separated from debris by
further density centrifugation before being utilised for phenotypic
and functional analysis.
Transfection
Panc-1 cells were transfected using a modiﬁed pCEP4 plasmid
vector containing human DNA coding for E-cadherin (a kind gift
from JMG Higgins, Boston, MA, USA). The plasmid was trans-
fected into Panc-1 cells using SuperFect (Qiagen, Crawley, UK).
Two micrograms of plasmid DNA and 8 ml of liposomes dissolved
in DMEM (serum and antibiotic free) was used for each transfec-
tion according to the Qiagen protocol. Brieﬂy the DNA/liposome
mixture was allowed to stand for 15 min at room temperature.
Semi-conﬂuent Panc-1 cells in a six well plate were washed with
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DMEM was added to the DNA/liposome mixture above which
was then added to each well. After incubation at 378C for 3 h
the cells were gently washed with PBS and replaced with complete
DMEM. After 24 h the transfected cells were selected using
350 mgm l
71 hygromycin B in complete DMEM. A study to deter-
mine the selection conditions for the parental cell line showed that
350 mgm l
71 of hygromycin B killed all wild-type cells after 7 days
(data not shown). Transfected colonies were isolated and sub-
cultured to allow phenotypic analysis.
Phenotypic analysis
Panc-1 cells (transfected and wild-type) were analysed for expres-
sion of the cell adhesion molecules E-cadherin and ICAM-1 and
also to conﬁrm that CD45 (a pan T cell marker) was not expressed.
Cells were grown to conﬂuence in 75 cm
72 tissue culture ﬂasks
(Corning) and then supernatant and non-viable cells removed.
Cells were detached from plastic by brief incubation with a
3m M solution of EDTA in PBS because Trypsin caused cleavage
of E-cadherin and resulted in inconsistent detection of E-cadherin
expression on cell lines. After detachment the cells were washed
and counted. 5610
5 cells were added to each FACS tube, washed
again and re-suspended in 50 ml of 5% foetal calf serum (FCS) in
PBS. Primary antibody was added and incubated at 48C for
30 min. The cells were washed again and 50 ml of FITC conjugated
goat anti-mouse secondary antibody added. This step was omitted
for conjugated primary antibodies. A further 30 min incubation at
48C was followed by washing and re-suspension of cells in 5% FCS
in PBS. The cells were then analysed by two-colour ﬂow cytometry.
For ﬂow cytometric analysis, the viable population was routinely
identiﬁed by propidium iodide (PI) exclusion; 5 mlo fa
25 mgm l
71 stock solution of PI in distilled water was added to
5610
5 cells in 200 ml PBS immediately prior to analysis.
The efﬁciency of Dynabead T lymphocyte negative selection
was assessed by assaying the selected population for CD3 expres-
sion. T-cells in the MLR (Day 8/9) were assayed similarly for
expression of CD45, CD103, CD11a (a chain LFA-1) and CD18
(b chain LFA-1).
Flow cytometric adhesion assay
A sensitive and reproducible ﬂow cytometric adhesion assay
previously developed by our group was modiﬁed for this study
(Korlipara et al, 1996). Brieﬂy, 2610
5 pancreatic cancer cells
(transfected or wild-type) were seeded onto a 24-well tissue culture
grade plate (Corning) and allowed to grow to conﬂuence over
24 h. The plate was washed and 5610
5 MLR-derived lymphocytes
were added to each well of the 24-well plate in RPMI 1640. For
assay of speciﬁc adhesion blockade, the lymphocytes were incu-
bated for 30 min at 378C with an appropriate blocking antibody
at a pre-optimised concentration before addition to the adhesion
assay plates; for control an isotype-matched antibody was used at
the same concentration.
In all cases the lymphocytes were allowed to contact the cancer
cells for 1 h at 378C. After this time the non-adherent cells were re-
suspended by use of a mechanical plate shaker for 5 min at 150
oscillations per minute (IKA-Shuttler MTS4; NE Lab supplies,
UK). The plate was then gently washed three times with PBS to
remove any non-adherent cells and 3 mM EDTA in PBS used to
detach cells from each other and the plate to produce a single cell
suspension. The cell suspension was added to FACS tubes, centri-
fuged and re-suspended in 50 ml of 5% FCS in PBS. A total of
2.5 ml of PE-conjugated anti-CD45 antibody was added to each
tube (to label the lymphocytes) and incubated for 30 min at 48C.
The cells were then washed again and analysed by ﬂow cytometry.
The cell populations were distinguished by size (forward scatter)
and ﬂuorescence channel 2 (CD45-PE) intensity. Ten replicates
of each experiment were performed and a mean and s.e.m. of
the ratio of lymphocytes to pancreatic cells calculated. Student’s
unpaired t-test was used to compare adhesion between different
populations.
Chromium release cytotoxicity assay
The lytic activity of CD103+ lymphocytes was assessed in an 8 h
51Cr-release assay. Panc-1 cells were detached with 3 mM EDTA
and a pellet of carcinoma cells was resuspended at 378C with
100 mCi [
51Cr] sodium chromate (CJS-4; Amersham International,
UK) per 10
6 cells for 90 min with agitation every 15 min. The
cells were re-suspended in 20 ml RPMI 1640 and incubated for
30 min at 378C before being washed ﬁve times by centrifugation.
Five thousand tumour cells were incubated with MLR lympho-
cytes at effecter:target ratios ranging from 100:1 to 25:1 in
round-bottomed 96-well microtiter plates. After 8 h, 100 mlo f
supernatant of each well was collected, and radioactivity was
measured with a gamma counter (Wallac g counter). Speciﬁc lysis
was calculated using the formula: speciﬁc
51Cr-release=[(experi-
mental counts – spontaneous counts)/(maximal counts –
spontaneous counts)6100%]. Some T cells were re-activated
prior to use in the cytotoxicity assay, by incubation at 378C for
1 h with anti-CD3 antibody. To determine CD103 restriction of
tumour cell lysis, in some assays the target cells were pre-incu-
bated with a CD103 blocking antibody or murine IgG1 isotype
control at optimal concentration pre-determined using the adhe-
sion assay.
RESULTS
Phenotypic analysis
Pancreatic cancer cell lines Figure 1 shows the results of ﬂow
cytometric analysis of adhesion molecule expression by viable
Panc-1 cells. Figure 1a shows that the wild-type Panc-1 cells
expressed no cell-surface E-cadherin. However, the stably trans-
fected Panc-1 cells homogeneously expressed high levels of this
adhesion molecule. Figure 1c,d show that both wild-type and E-
cadherin transfected Panc-1 cells expressed equally high levels of
cell-surface ICAM-1. In all cases a 3 mM solution of EDTA in
PBS was used to detach the cells from culture plastic as treatment
with trypsin was found to cleave E-cadherin from the cells result-
ing in inconsistent detection of E-cadherin expression. Neither
wild-type nor the transfected cells expressed CD45 (data not
shown).
Lymphocytes Lymphocyte phenotype was analysed by ﬂow cyto-
metry. Each analysis was performed on three separate occasions.
Non-viable lymphocytes always comprised fewer than 5% of the
population and were excluded from analysis on the basis of propi-
dium iodide (PI) staining. Routine analysis of the results of
immunomagnetic T cell selection showed that CD3+ve cells made
up more than 99% of the negatively selected population.
Figure 2a shows a representative time-course for the induction
of CD103 expression following addition of TGFb1 to an MLR
culture at day 3. Serial harvest and phenotypic analyses of the
T cells showed that at day 9 the CD103+ population had
increased to a mean of 39.7%, and by day 11 to a mean of
50.6%. Lymphocytes from MLR without addition of TGFb1
showed only a slight increase in CD103 expression, which reached
a plateau of 8.8% by day 9 of culture. Figure 2b shows the results
of a further phenotypic characterisation performed 9 days after
the initiation of MLR culture in the presence of TGFb1. The 2-
parameter ﬂow cytometric dot-plot shows that 42.6% of the T
cells expressed CD103, that 39.1% of the T cells were CD8+ve
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
T cell adhesion to pancreatic cancer cells
JJ French et al
1036
British Journal of Cancer (2002) 87(9), 1034–1041 ã 2002 Cancer Research UKand that 75.9% of the CD8+ve T cells also expressed CD103.
Fewer than 22% of the CD8-ve T cells expressed CD103, suggest-
ing that CD103 is preferentially expressed by class I MHC-
restricted cytotoxic T cells. Additional experiments (data not
shown) demonstrated that TGFb1 did not alter the proportion
of CD8+ T cells in the MLR (37% in representative non-
TGFb1-supplemented cultures) but that fewer than 5% of these
cells expressed CD103. Furthermore, the T cells in both TGFb1
supplemented and non-supplemented cultures expressed similarly
high levels of both the CD11a and CD18 integrin-chains of
LFA-1. The leukocyte common antigen CD45 was also expressed
by all T cells in both cultures.
Flow cytometric adhesion assays
Figure 3 shows the results from a typical ﬂow cytometric analysis
of the mixed T cell and epithelial cell population derived from
one well of a 24-well adhesion assay plate. The two-parameter
dot-plot shows a clear discrimination between the CD45+ve T cells
(delineated by R2) and the population of larger, but CD45-ve
epithelial cells (delineated by R1). Following enumeration of the
cells in each region, the lymphocyte: epithelial cell binding ratio
(R2/R1) can be calculated.
Figure 4a shows that addition of TGFb1 during MLR culture,
and hence up-regulation of CD103 expression, made no difference
to the binding of day 9 T cells to wild-type Panc-1 cells (P40.6).
However, T cells from TGFb1 supplemented MLR cultures showed
a signiﬁcantly increased binding to E-cadherin expressing Panc-1
transfectants (P50.0001).
The binding of T cells from TGFb1 supplemented day 9 MLR to
wild-type Panc-1 cells was not inhibited by antibody-mediated
blockade of either CD103 or ICAM-1 (P40.2; Figure 4b).
However, antibody-blockade of CD103 reduced the adhesion of
these cells to E-cadherin expressing Panc-1 transfectants to near
basal levels (P50.001). Signiﬁcantly, blockade of ICAM-1 had no
effect on T cell adhesion to the transfected Panc-1 cells (P40.2;
Figure 4b).
Chromium release cytotoxicity assay
Figure 5a shows representative results from a
51Cr release cytotoxi-
city assay using T cells harvested from a non-TGFb1 supplemented
day 9 MLR. The assay was routinely performed across a range of
effecter: target cell ratios, but 50:1 regularly produced optimal
cytotoxicity and these data are presented. The allo-speciﬁc T cells
produced efﬁcient positive control lysis of the EBV cell line used
to stimulate the MLR. However, little background lysis of either
wild-type or E-cadherin expressing Panc-1 transfectants was
observed. T cell re-activation with anti-CD3 increased only slightly
the lysis of these 2 cell lines (Panc-1 WT, P40.09; Panc-1.E-cad
P40.8; Figure 5a).
The results of a similar experiment performed using T cells from
a TGFb1 supplemented MLR are shown in Figure 5b. In this
experiment, stimulation of CD3 failed to increase the limited
(520%) lysis of the wild-type targets (P40.15), but greatly
enhanced cytolysis of the E-cadherin expressing Panc-1 transfec-
tants to a level comparable with that of the speciﬁc EBV target
cells (435%; P50.0001).
To verify the function of adhesion between CD103 and E-
cadherin in the lysis of pancreatic cancer cells, a further series of
cytolysis experiments was performed in the presence of CD103
antibody blockade. Figure 6 shows results from a representative
assay in which blockade of CD103 reduced the lysis of E-cadherin
expressing Panc-1 cells by T cells from a TGFb1 supplemented
MLR (P50.0001) to levels comparable with the lysis of wild-type
target cells (P40.08). ICAM-1 blockade did not reduce the lysis
of E-cadherin expressing Panc-1 cells (p40.1). Control lysis of
the speciﬁc EBV transformed target cells was not inhibited by
CD103 blockade.
DISCUSSION
Immunohistological studies of the distribution of T cells in normal
and inﬂamed pancreatic tissue suggest that CD103+ lymphocytes
play an important role in the pancreatic epithelium (Ademmer et
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inﬁltrating T cells included both CD4+ (helper) and CD8+ (cyto-
toxic) phenotypes and were distributed in the interstitial tissue,
periductal regions, or intercalating between the epithelial cells.
Large numbers of lymphocytes were seen in inﬂamed and malig-
nant pancreas, where CD4+CD103- T cells form the
predominant subset. However, CD103+ lymphocytes, generally
co-expressing CD8, were observed in the intraepithelial compart-
ment, implying that this subset is analogous to gut IEL
(Ademmer et al, 1998; Ebert et al, 1998).
Induction of CD103 on lymphocytes from peripheral blood was
achieved in this study by activation of allospeciﬁc T cells in an
MLR, followed by culture in the presence of TGFb1; the MLR
system was chosen to model antigen-speciﬁc activation of large
numbers of primary human T cells. The results from this model
are consistent with previous studies (Austrup et al, 1995), although
the methodology described in the current report is novel. Previous
in vitro studies demonstrate that the majority of T cells of the
CD103 phenotype are activated CD8+ cells (Cerf-Bensussan et al,
1987; Rihs et al, 1996; Ademmer et al, 1998; Fujihara et al,
1999). The population produced in vitro using the technique in
the current study was essentially similar to IEL with regards to acti-
vation and predominance of the CD8 phenotype. Therefore, in
principle, these cells can be used to model IEL in terms of pheno-
type and adhesive properties.
The important components of the system used to generate
CD103+ T cell in vitro were activation of the lymphocytes and,
crucially, the addition of TGFb1. The T cells found in the pancreas
are predominantly CD45RO positive (Ebert et al, 1998), indicating
prior activation. It has also been shown previously that the CD103
positive IEL isolated from gut epithelium express surface markers
consistent with prior activation (Schieferdecker et al, 1990). It is
likely that activated IEL acquire the CD103 phenotype in vivo in
response to the presence of high levels of TGFb1 in the epithelial
microenvironment. This is consistent with the high levels of TGFb1
observed in pancreatic adenocarcinoma (Friess et al, 1993) and
chronic pancreatitis (van Laethem et al, 1995).
Activation of T cells followed by addition of TGFb1 signiﬁcantly
increased adhesion to an E-cadherin transfected pancreatic carcino-
ma cell line; this treatment had no effect on adhesion to E-cadherin
deﬁcient wild-type Panc-1 cells. This observation suggests that the
CD103?E-cadherin interaction is important for lymphocyte adhe-
sion to Panc-1 target cells. However, it is possible that target cell
transfection and treatment with TGFb1 altered T cell adhesion
properties by some alternative mechanism. In order to address this
a series of experiments was performed to deﬁne the effect of block-
ade of the CD103 integrin with an excess of anti-CD103 antibody.
This treatment abrogated the enhanced adhesion to E-cadherin
expressing targets, conﬁrming that the increased adhesion to E-
cadherin expressing targets was due to the expression of functional
CD103.
Normal pancreatic epithelium expresses high levels of E-cadher-
in, which is associated with the plasma membrane (Weinel et al,
1996). These cells do not express ICAM-1 (Shimoyama et al,
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
%
 
T
-
c
e
l
l
s
 
t
h
a
t
 
c
o
-
e
x
p
r
e
s
s
 
C
D
1
0
3
75
50
25
0
0              2              4              6              8             10            12
Days in culture
12.96% 29.66%
47.90%
10
4
103
102
101
C
D
1
0
3
+
v
e
C
D
1
0
3
-
v
e
100 101 102 103 104
CD8-ve CD8+ve
9.48%
B
A
Figure 2 Flow cytometric examination of the induction of CD103 ex-
pression by T cells in MLR culture. (A) Shows the time course for induction
of CD103 on lymphocytes cultured in MLR with TGFb1 added on day 3
(solid line) or without TGFb1 (dotted line). The data points show the mean
of 10-fold determinations; the error bars show the s.e.m. (B) Shows results
from a representative two-parameter ﬂow cytometric dot-plot for viable
cells harvested from a day 9 MLR which was supplemented with TGFb1
on day 3. It can be seen that the majority (75.6%) of the CD8 T cells at
this time point also express CD103.
Ratio 1.8 : 1
R1: Epithelial cells
3490 events
R2: Lymphocytes
6294 events
1023
0
F
S
C
-
H
e
i
g
h
t
100 101 102 103 104
FL2-Height
Figure 3 Representative two-parameter dot-plot from a typical ﬂow cy-
tometric analysis of the mixed T cell and epithelial cell population derived
from one well of a 24-well adhesion assay plate. The analysis regions allow
clear discrimination between the epithelial cells (R1) and lymphocytes (R2)
and calculation of a lymphocyte:epithelial cell binding ratio of 1.8.
T cell adhesion to pancreatic cancer cells
JJ French et al
1038
British Journal of Cancer (2002) 87(9), 1034–1041 ã 2002 Cancer Research UK1997) but this molecule can be induced by treatment with the
proinﬂammatory cytokines TNFa and IFNg (Schwaeble et al,
1993). The LFA-1?ICAM-1 interaction is known to be important
for adhesion of lymphocytes to vascular endothelium as a precur-
sor to extravasation and penetration of the extra-vascular space
(Springer, 1990). Hence, expression of ICAM-1 within the pancrea-
tic epithelium could allow T cell adhesion in the absence of E-
cadherin.
Both CD103+ and CD103- T cells showed a small but similar
adhesion to E-cadherin negative wild-type Panc-1 cells. Phenotypic
analysis of the Panc-1 cells showed high levels of ICAM-1 expres-
sion, whilst both CD103+ and CD103- T cells expressed high levels
of LFA-1. These ﬁndings suggest that the LFA-1?ICAM-1 interac-
tion could stabilise T cell adhesion to Panc-1 cells. However,
adhesion studies performed in the presence of anti-ICAM-1 block-
ade did not signiﬁcantly reduce either CD103+ or CD103- T cell
adhesion to E-cadherin negative wild-type Panc-1 cells, suggesting
that LFA-1 does not enhance adhesion in this system.
T-cell-mediated target cell lysis can be modelled in the absence
of a speciﬁc antigen by re-stimulating activated T cells with CD3
antibodies immediately prior to
51Cr-release assay (Roberts and
Kilshaw, 1993). This ‘re-directed lysis’ technique was used in the
current study to assess speciﬁc cytolysis of Panc-1 cells using
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Figure 5 Examination of cytolysis of Panc-1 cells by activated T cells with
or without additional T cell receptor stimulation by CD3. (A) Assay per-
formed using T cells from a day 9 MLR in the absence of exogenous TGFb1.
Hatched bar shows control cytolysis of the antigen-presenting cells used for
T cell activation, open bars show Panc-1 lysis in the absence of CD3 stimu-
lation and solid bars show the lysis produced following CD3 stimulation.
The bars show the mean of 10-fold determinations; the error bars show
the s.e.m. (B) Results of a similar assay performed using T cells harvested
from an MLR performed in the presence of exogenous TGFb1. The bars
show the mean of 10-fold determinations; the error bars show the s.e.m.
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Figure 6 Investigation of the effect on Panc-1 cytolysis of antibody block-
ade of ICAM-1 or CD103. The effector T cells were harvested from an MLR
performed in the presence of TGFb1 and were additionally stimulated with
anti-CD3 antibody prior to addition to the target cells. The hatched bar
shows control cytolysis of the antigen-presenting cells used for T cell activa-
tion, the open bar shows the lysis of E-cadherin transfected Panc-1 in the
presence of a control antibody, the shaded bar shows the effect of
ICAM-1 blockade, the solid bar shown the effect of CD103 blockade and
the horizontally ﬁlled bar shows lysis of wild-type Panc-1 cells. The bars
show the mean of 10-fold determinations; the error bars show the s.e.m.
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Figure 4 Examination of the adhesion of activated T lymphocytes to
Panc-1 cells. (A) Demonstration of binding of T cells from non-TGFb1 sup-
plemented (open bars) and TGFb1-supplemented (solid bars) MLR cul-
tures to wild-type and E-cadherin transfected Panc-1 cells. The bars
show the mean of 10-fold determinations; the error bars show the s.e.m.
(B) Examination of antibody-blockade of the adhesion of T cells from a
TGFb1 supplemented MLR to wild-type and E-cadherin transfected Panc-
1 cells. Control assays are indicated by open bars, solid bars show blockade
of CD103 and hatched bars show blockade of ICAM-1. The bars show the
mean of 10-fold determinations; the error bars show the s.e.m.
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that E-cadherin expressing Panc-1 transfectant cells were efﬁciently
lysed following re-stimulation of CD103+ T cells produced by
TGFb1 treatment; these effecter lymphocytes did not lyse wild-type
Panc-1 cells. Furthermore, it was found that restimulation with
anti-CD3 antibodies was essential for target cell lysis, indicating a
requirement for speciﬁc T cell receptor stimulation. These observa-
tions suggest that the CD103?E-cadherin interaction is essential
for speciﬁc T cell-mediated lysis of pancreatic cancer cell targets.
However, it is possible that transfection of the Panc-1 cells altered
their susceptibility to lysis by an alternative mechanism. To test
this possibility, assays were performed in which the CD103 integrin
was blocked by addition of anti-CD103 antibodies. This treatment
abrogated the enhanced lysis of E-cadherin expressing targets,
conﬁrming that the increased lysis of E-cadherin expressing
Panc-1 target cells was produced by speciﬁc adhesion of CD103+
T cells.
Immunohistochemical studies have demonstrated that pancrea-
tic carcinoma in vivo has reduced E-cadherin expression when
compared to normal pancreas, and that loss of this antigen corre-
lates with advanced stage, high grade and the presence of lymph
node metastasis (Pignatelli et al, 1994). In the current study it has
been demonstrated that re-expression of E-cadherin by an E-
cadherin negative pancreatic carcinoma cells is necessary both
for the adhesion of CD103-expressing lymphocytes and the
susceptibility of these cancer cells to subsequent lysis. Hence,
the decreased expression of E-cadherin by pancreatic carcinoma
cells in vivo could reduce or abolish the ability of tumour anti-
gen-speciﬁc T-lymphocytes in the TGFb-rich cancer
microenvironment to adhere to and lyse their targets, allowing
cancer cells to escape from normal intraepithelial immunological
surveillance. This suggests a mechanism for immunological selec-
tion of cancer cells with a reduced E-cadherin expression
(Seymour et al, 1999; Pettit et al, 2000). The results of our study
have implications for the design of immunotherapeutic strategies
based on T cell killing of pancreatic cancer cells within a
TGFb-rich microenvironment, as this process may be highly
dependent on T cell adhesion to E-cadherin.
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